{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003376","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.128855+00:00","generated_at":"2026-06-07T01:41:53.701194+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuvalent reports $719.9M cash; launches 'OnTarget 2026' plan targeting first approval in 2026","bullets":["Cash, cash equivalents and marketable securities of $719.9M as of Dec 31, 2023 (unaudited); expected to fund operations into 2027.","OnTarget 2026 plan aims for first potential approved product in 2026, with pivotal data from at least one lead program in 2025.","2024 milestones: advance Phase 2 ARROS-1 (NVL-520) and initiate Phase 2 ALKOVE-1 (NVL-655), launch front-line ALK strategy, start Phase 1 for HER2 program.","Interim data from ARROS-1 and ALKOVE-1 expected at medical meetings in 2024.","Company to present at J.P. Morgan Healthcare Conference on Jan 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003376","json":"https://secwatch.observer/filing/0000950170-24-003376.json","markdown":"https://secwatch.observer/filing/0000950170-24-003376.md","text":"https://secwatch.observer/filing/0000950170-24-003376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/0000950170-24-003376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/nuvl-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:41:53.701194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}